FDA roadmap highlights opioids, gene therapy, biosimilars – BioPharma Dive
|
FDA roadmap highlights opioids, gene therapy, biosimilars
BioPharma Dive The Food and Drug Administration's 2018 strategic policy roadmap highlights the battle against opioid addiction, the growth of cell and gene therapy, and using competition to improve access and make drugs more affordable. Identifying where pharma is … |
